Retinol Before PRP: Why It Matters and How Long to Stop

Retinol is one of the most widely used active ingredients in cosmetic skincare — and one of the most commonly overlooked contraindications before PRP therapy. The issue is not cosmetic interference or peptide degradation. It is a structural one: retinol progressively thins the stratum corneum, compromising the skin's most critical barrier to systemic absorption. When topical local anaesthetic is then applied to that compromised skin before a PRP procedure, the consequences can extend well beyond the treatment room.

What Retinol Does to Skin — and Why the Stratum Corneum Matters

Retinol (vitamin A alcohol) is converted in the skin to retinaldehyde and then to all-trans retinoic acid (tretinoin), the biologically active form that binds nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to regulate gene expression.¹ This receptor-mediated activity drives much of what makes retinoids therapeutically valuable: increased epidermal turnover, upregulation of collagen I and III synthesis, and correction of the compact, basket-weave collagen organisation disrupted by photoageing.²

But the same mechanism that accelerates cell turnover also acts on the stratum corneum — the outermost, non-viable layer of keratinocytes that constitutes the skin's principal physical and chemical barrier. The stratum corneum is not simply dead skin waiting to be shed. It is a precisely organised structure of flattened, lipid-enveloped corneocytes arranged in a brickwork pattern, cemented together by an intercellular lipid matrix of ceramides, cholesterol, and free fatty acids.³ This architecture is what governs percutaneous absorption: the rate at which molecules cross from the skin surface into the systemic circulation.

Retinoids accelerate corneocyte shedding and shorten the transit time of keratinocytes through the epidermis. The resulting stratum corneum is thinner, has fewer corneocyte layers, and exhibits measurably disrupted barrier function — reflected in elevated transepidermal water loss (TEWL), a validated surrogate for barrier competence.⁴ Griffiths and colleagues demonstrated that topical tretinoin at both 0.025% and 0.1% concentrations produced significant increases in TEWL compared with vehicle controls, with the degree of barrier disruption dose-dependent and observable within weeks of commencement.⁵ Retinol, while less potent than tretinoin gram-for-gram, operates through the same pathway and produces the same structural effect — the difference is one of magnitude and onset, not mechanism.¹

The Local Anaesthetic Toxicity Problem

PRP therapy to the face requires adequate anaesthesia. For PRP facial injections, a topical local anaesthetic — most commonly a eutectic mixture of lidocaine and prilocaine (EMLA) or a compounded 4–5% lidocaine preparation — is applied under occlusion for 30–60 minutes prior to the procedure. The occlusive dressing itself accelerates absorption by increasing skin hydration and temperature, raising local blood flow, and driving the concentration gradient across the stratum corneum.⁶

In intact skin, the stratum corneum provides sufficient resistance to limit systemic absorption of topically applied local anaesthetics to clinically safe levels. When the barrier is compromised — by retinoid use, dermatitis, or any other cause of barrier dysfunction — the pharmacokinetics change substantially. Juhlin and colleagues demonstrated that lidocaine and prilocaine plasma levels after EMLA application were significantly higher over diseased skin (psoriasis, atopic dermatitis) than over intact skin, with plasma concentrations in some subjects approaching levels associated with early systemic toxicity.⁷

Local anaesthetic systemic toxicity (LAST) is the clinical syndrome that results when plasma concentrations of local anaesthetic exceed the threshold for cardiovascular and central nervous system effects. The American Society of Regional Anaesthesia (ASRA) practice advisory describes a dose- and rate-dependent progression: early neurological symptoms (circumoral numbness, tinnitus, metallic taste, agitation) may rapidly precede cardiovascular effects including conduction abnormalities, ventricular arrhythmia, and — in severe cases — refractory cardiac arrest.⁸ Topically administered agents are generally considered low-risk compared with regional nerve block doses, but that risk calculation assumes an intact barrier. In retinoid-compromised skin, particularly under occlusion and across the relatively large surface area of a full face treatment, the safety margin narrows meaningfully.

Prilocaine carries the additional risk of methemoglobinaemia — oxidation of ferrous haemoglobin to the ferric form, which cannot carry oxygen. This risk is similarly proportional to the absorbed dose, and again becomes more relevant when barrier function is impaired.⁶

PRP Microneedling: A Compounded Risk

PRP microneedling combines mechanical epidermal disruption with the topical application of platelet-rich plasma, typically performed with needles of 0.5 to 2.5 mm depth across the full face. It is worth addressing this modality for context, though it is not performed at this clinic — the risks of retinoid pre-treatment are substantially amplified in this setting.

Microneedling creates thousands of micro-channels through the epidermis and into the upper dermis, bypassing the stratum corneum barrier entirely. In retinoid-compromised skin, this effect is markedly more pronounced: the epidermis is thinner, the corneocyte layers are reduced, and the inflammatory threshold is lower. The resulting skin is more susceptible to post-procedure erythema, prolonged inflammation, and post-inflammatory hyperpigmentation.⁹ When topical anaesthetic is applied to this already-compromised skin before microneedling, the micro-channels created during the procedure provide direct conduits into the dermal vasculature, and systemic absorption can occur at a rate approximating that of an intradermal injection rather than a topical application.

A further consideration in the microneedling context is wound healing. Retinoic acid signalling is intimately involved in epidermal differentiation and the regulation of matrix metalloproteinases (MMPs). There is evidence that retinoid-treated skin heals more slowly than untreated skin after mechanical disruption — a finding consistent with the known effects of systemic retinoids (isotretinoin) on wound healing and surgical healing time, where a 6-month cessation period is standard before elective procedures.¹⁰ While topical retinol operates at far lower systemic concentrations than oral isotretinoin, the directional effect on the healing epidermis is the same.

PRP Facial Injections: The Relevant Clinical Scenario

In the context of PRP facial injections — the modality performed at this clinic — the stratum corneum disruption caused by retinol is relevant specifically through two pathways: local anaesthetic absorption and skin integrity at injection sites.

For anaesthetic absorption: as described above, retinol-thinned skin under occlusive topical anaesthetic exhibits increased systemic absorption. The full-face nature of PRP injection treatment — involving injections across the forehead, periorbital area, cheeks, nasolabial folds, and perioral region — means topical anaesthetic is applied across a large surface area. This is precisely the scenario in which cumulative absorbed dose becomes clinically relevant.

For injection site integrity: while PRP injections do not create the same degree of epidermal disruption as microneedling, they do breach the skin surface repeatedly across the treatment field. Retinoid-compromised skin has a lower barrier to epidermal penetration, a reduced inflammatory threshold, and — particularly with higher-concentration retinol formulations — may already be in a subclinical state of retinoid dermatitis characterised by baseline erythema, scaling, and impaired barrier repair. Injecting through inflamed skin carries modestly elevated infection and post-inflammatory pigmentation risk, and the post-procedure recovery period is likely to be more uncomfortable than in untreated skin.

There is also a theoretical but under-studied question of whether retinoid-induced alterations in platelet behaviour or growth factor activity at the injection site could influence PRP efficacy. Retinoic acid has demonstrated regulatory effects on platelet activation and thromboxane A2 signalling in vitro,¹¹ though the clinical significance of this at cosmetic retinol concentrations is not established. The safety considerations alone provide a sufficient basis for cessation guidance without needing to resolve this question.

Withholding Periods: Before and After PRP

Evidence-based cessation timelines for topical retinol before PRP are derived from the pharmacokinetics of skin barrier recovery and the known clinical course of retinoid-induced barrier disruption. Controlled data are limited — the guidance that follows reflects current consensus from procedural dermatology and aesthetic medicine, grounded in the barrier physiology reviewed above.

The rationale for the 5–7 day pre-injection cessation window relates to the physiology of stratum corneum recovery. The stratum corneum turns over approximately every 14 days, but measurable improvements in TEWL and barrier function can be observed within 5–7 days of discontinuing an active irritant — sufficient to reduce (though not fully eliminate) the absorption-enhancement effect.³ For patients using higher-concentration formulations or who have been using retinol daily for extended periods, a 7-day cessation is preferable to 5.

The post-procedure cessation window of 7–14 days after PRP injections reflects the time required for full epidermal recovery at injection sites and normalisation of the local inflammatory response. Reintroducing retinol too early risks prolonged erythema, delayed resolution of injection site changes, and unnecessary irritation to skin that is in an active recovery phase. After PRP microneedling, where the epidermal disruption is far more extensive, a 4–6 week window is appropriate — consistent with guidance applied after other ablative and semi-ablative procedures.

Practical Patient Guidance

Patients presenting for PRP facial injections should be asked specifically about retinol and retinoid use at the pre-procedure consultation — not simply whether they use "active ingredients." Many patients do not categorise their retinol serum or retinol-containing night cream as a medical product, and will not volunteer the information unless asked directly. The question should cover retinol, retinaldehyde, and prescription-strength tretinoin, which requires a longer cessation window given its greater potency.

The pre-procedure skincare protocol communicated to patients at this clinic is straightforward: cease all retinoid-containing products five to seven days before your appointment. This includes serums, night creams, and any prescription retinoic acid products. Do not resume until the skin has fully settled — typically one to two weeks after PRP injections, or as directed at your post-procedure review.

It is also worth noting that the same barrier disruption rationale applies to other active ingredients capable of compromising stratum corneum integrity — including glycolic acid, lactic acid, and high-concentration salicylic acid preparations. These warrant a similar 3–5 day cessation window before PRP, though the magnitude of barrier effect is generally less than that produced by retinoids at typical cosmetic concentrations.